Premium
Enhancing the scopolamine production in transgenic plants of Atropa belladonna by overexpressing pmt and h6h genes
Author(s) -
Wang Xirong,
Chen Min,
Yang Chunxian,
Liu Xiaoqiang,
Zhang Lei,
Lan Xiaozhong,
Tang Kexuan,
Liao Zhihua
Publication year - 2011
Publication title -
physiologia plantarum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.351
H-Index - 146
eISSN - 1399-3054
pISSN - 0031-9317
DOI - 10.1111/j.1399-3054.2011.01506.x
Subject(s) - atropa belladonna , hyoscyamine , scopolamine , transgene , genetically modified crops , biosynthesis , gene , biology , chemistry , solanaceae , biochemistry , botany , pharmacology
Atropa belladonna is officially deemed as the commercial plant to produce scopolamine in China. In this study we report the simultaneous overexpression of two functional genes involved in biosynthesis of scopolamine, which encode the upstream key enzyme putrescine N‐methyltransferase (PMT) and the downstream key enzyme hyoscyamine 6 β ‐hydroxylase (H6H), respectively, in transgenic herbal plants Atropa belladonna . Analysis of gene expression profile indicated that both pmt and h6h were expressed at a higher level in transgenic lines, which would be favorable for biosynthesis of scopolamine. High‐performance liquid chromatography result suggested that transgenic lines could produce higher accumulation of scopolamine at different levels compared with wild‐type lines. Scopolamine content increased to 7.3‐fold in transgenic line D9 compared with control lines. This study not only confirms that co‐overexpression of pmt and h6h is an ideal method to improve the biosynthetic capacity of scopolamine but also successfully cultivates the transgenic line D9, which significantly enhanced the scopolamine accumulation. Our research can serve as an alternative choice to provide scopolamine resources for relative industry, which is more competitive than conventional market.